A pretreatment nomogram predicting recurrenceand progression-free survival for nonmuscle invasive bladder cancer in Japanese patients

International Journal of Clinical Oncology

Volumn 15, Issue 3, 2010, Pages 271-279

  Yamada, Toru ^a,b   Tsuchiya, Kunihiro ^a   Kato, Seiichi ^a   Kamei, Shingo ^a   Taniguchi, Mitsuhiro ^a   Takeuchi, Toshimi ^c   Yamamoto, Naoki ^d   Ehara, Hidetoshi ^d   Deguchi, Takashi ^d  

^a Gifu Urothelial Cancer Research Group   (Japan)

^b Kakegawa City General Hospital   (Japan)

^c Gifu Municipal Hospital   (Japan)

^d GIFU UNIVERSITY   (Japan)

Author keywords

Bladder; Cancer; Invasive; Nomogram; Nonmuscle; Survival

Indexed keywords

BCG VACCINE; EPIRUBICIN; PIRARUBICIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLADDER CANCER; CANCER GRADING; CANCER INVASION; CANCER MORPHOLOGY; CANCER PATIENT; CANCER RECURRENCE; CANCER REGISTRY; CONTROLLED STUDY; FEMALE; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CANCER; MULTIVARIATE ANALYSIS; NOMOGRAM; PREDICTION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RECURRENCE RISK; RETROSPECTIVE STUDY; VALIDATION STUDY; BLADDER; CANCER STAGING; DECISION SUPPORT SYSTEM; DISEASE FREE SURVIVAL; JAPAN; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PATHOLOGY; PREDICTIVE VALUE; PROPORTIONAL HAZARDS MODEL; RECEIVER OPERATING CHARACTERISTIC; REGISTER; REPRODUCIBILITY; RISK ASSESSMENT; RISK FACTOR; TIME; TREATMENT OUTCOME; TUMOR INVASION; TUMOR RECURRENCE; URINARY BLADDER NEOPLASMS; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; DECISION SUPPORT SYSTEMS, CLINICAL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; JAPAN; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NOMOGRAMS; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; REGISTRIES; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; ROC CURVE; TIME FACTORS; TREATMENT OUTCOME; URINARY BLADDER; URINARY BLADDER NEOPLASMS; YOUNG ADULT; KAPLAN-MEIER ESTIMATE;

EID: 77955712713     PISSN: 13419625     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10147-010-0049-6     Document Type: Article

References (17)

1. Sylvester RJ, van der Meijden AP, Oosterlinck W et al (2006) Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49:466-477
2. Witjes JA (2006) Management of BCG failures in superficial bladder cancer: a review. Eur Urol 49:790-797
3. Millán-Rodríguez F, Chéchile-Toniolo G, Salvador-Bayarri J et al (2000) Multivariate analysis of the prognostic factors of primary superficial bladder cancer. J Urol 163:73-78
4. Kaasinen E, Rintala E, Hellström P et al (2002) Factors explaining recurrence in patients undergoing chemoimmunotherapy regimens for frequently recurring superficial bladder carcinoma. Eur Urol 42:167-174
5. Millán-Rodríguez F, Chéchile-Toniolo G, Salvador-Bayarri J et al (2000) Primary superficial bladder cancer risk groups according to progression, mortality and recurrence. J Urol 164:680-684
6. Kurth KH, Denis L, Bouffioux C et al (1995) Factors affecting recurrence and progression in superficial bladder tumors. Eur J Cancer 31:1840-1846
7. Harrell FE Jr, Lee KL, Mark DB (1996) Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 15:361-387
8. Hanley JA, McNeil BJ (1982) The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 143:29-36
9. Oosterlinck W, van der Meijden A, Sylvester R et al (2006) Guidelines on TaT 1 (non-muscle invasive) bladder cancer. http:// www.uroweb.org/nc/ professional-resources/guidelines/online/. Accessed 1 May 2009
10. National Comprehensive Cancer Network (2009) NCCN clinical practice guidelines in oncology. Bladder cancer. V.1.2009. http://www.nccn.org/ professionals/physician-gls/PDF/bladder.pdf. Accessed 1 May 2009
11. Konety BR, Joyce GF, Wise M (2007) Bladder and upper tract urothelial cancer. J Urol 177:1636-1645
12. Soloway MS, Bruck DS, Kim SS (2003) Expectant management of small, recurrent, noninvasive papillary bladder tumors. J Urol 170:438-441
13. Donat SM, North A, Dalbagni G et al (2004) Efficacy of office fulguration for recurrent low grade papillary bladder tumors less than 0.5 cm. J Urol 171:636-639
14. Gofrit ON, Pode D, Lazar A et al (2006) Watchful waiting policy in recurrent Ta G1 bladder tumors. Eur Urol 49:303-307
15. Sakai I, Miyake H, Harada K et al (2006) Analysis of factors predicting intravesical recurrence of superficial transitional cell carcinoma of the bladder without concomitant carcinoma in situ. Int J Urol 13:1389-1392
16. Babjuk M, Oosterlinck W, Sylvester R et al (2008) Guidelines on TaT1 (non-muscle invasive) bladder cancer. http://www.uroweb. org/nc/professional- resources/guidelines/online/. Accessed 1 May 2009
17. Hall MC, Chang SS, Dalbagni G et al (2007) Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol 178:2314-2323